Suzhou Ribo Life Science Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
3
Ending by 2030
Oct 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 30, 2026The maintenance fee for Nucleic Acid, Composition and Conjugate Containing Same, Preparation Method, and Use Thereof (US 11,660,347) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
- 1 fee due Mar 1, 2027The maintenance fee for Methods for treating eye disorders (US 9,121,020) comes due Mar 1, 2027. Unpaid by Sep 1, 2027, it lapses early.
- 2 fees due Aug 13 to 25, 2027 · next Aug 13
- 1 fee due Sep 5, 2027The maintenance fee for Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof (US 11,918,600) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
- 1 fee due Nov 3, 2027The maintenance fee for Small interference RNAs, uses thereof and method for inhibiting the expression of plk1 gene (US 9,328,348) comes due Nov 3, 2027. Unpaid by May 3, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,121,020 | Methods for treating eye disorders In force · USPTO record | In force | USPTO record | |
| US 9,701,961 | Methods for treating eye disorders In force · USPTO record | In force | USPTO record | |
| US 8,765,931 | A Double-Stranded Oligonucleotide Compound for Down-Regulating the Expression of CASP2 Gene In force · High confidence | In force | High confidence | |
| US 9,328,348 | Small interference RNAs, uses thereof and method for inhibiting the expression of plk1 gene In force · USPTO record | In force | USPTO record | |
| US 9,382,542 | Double-stranded RNA compounds to CASP2 and uses thereof In force · USPTO record | In force | USPTO record | |
| US 10,570,394 | Double-stranded RNA compounds to CASP2 and uses thereof In force · USPTO record | In force | USPTO record | |
| US 11,414,661 | Nucleic Acid, Composition and Conjugate Containing Nucleic Acid, Preparation Method Therefor and Use Thereof In force · High confidence | In force | High confidence | |
| US 11,414,665 | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof In force · USPTO record | In force | USPTO record | |
| US 11,492,620 | Double-Stranded Oligonucleotide, Composition and Conjugate Comprising Double-Stranded Oligonucleotide, Preparation Method Thereof and Use Thereof In force · High confidence | In force | High confidence | |
| US 11,633,482 | Conjugates and Preparation and Use Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 23: 6 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
8 pending · 2 abandoned · 6 no status recorded